Articles tagged with Tumor Cells
Researchers have identified a key protein, DAPK3, that plays a crucial role in the body's early immune response to cancer. The discovery highlights a new approach to cancer immunotherapy, where targeting the tumor's own innate immune system can help slow tumor growth and improve treatment outcomes.
Scientists have identified new biomarkers in exosomes produced by cancer stem cells, which could help diagnose and predict malignant melanoma. These biomarkers were found to be present in the blood of patients with different stages of the disease, distinguishing them from healthy individuals.
Researchers at the University of Chicago developed a new therapeutic vaccine that uses a patient's own tumor cells to train their immune system to find and kill cancer. The vaccine stopped melanoma tumor growth in mouse models and promoted a broad, robust immune response, preventing new tumor growth when tumor cells were re-introduced.
Researchers developed a new vaccine that uses a patient's own tumor cells to train the immune system to find and kill cancer, promoting a broad and robust immune response. The therapy has shown long-term efficacy against metastasis and relapse in mouse models, offering potential for treatment of various cancers.
Researchers have identified YAP as a key regulator in the development and spread of basal-like breast cancer. Inhibiting YAP activity with medication can significantly reduce tumour volume, offering new hope for patients' survival.
Researchers at Imperial College London have developed a new type of nanoprobe that uses second harmonic generation (SHG) to detect tumors more brightly and precisely than existing fluorescent nanoprobes. The biodegradable bioharmonophores attach specifically to tumor cells, reducing misrepresentation and improving detection sensitivity.
Researchers discovered that metastatic cancer cells use adhesion and contractility to move away from stiffer tissue, defying the typical durotaxis process. By modulating cell contractility, they can change their ability to migrate in response to environmental stiffness.
Researchers have developed a lower-dose radiopharmaceutical that improves treatment efficacy for neuroendocrine cancers while reducing side effects. The new medication uses reversible binding technology to extend its half-life in the blood, providing an extended therapeutic time window and improved treatment outcomes.
Researchers assessed tumor cell isolation and in vitro proliferation assays to predict chemotherapy response in ovarian cancer. In 12 of 14 cases, in vitro drug sensitivity correlated with clinical outcome.
Researchers found that tumor cells increase SLC6A14 expression levels in response to methionine deprivation, leading to increased AMPK activation. Targeting both SLC6A14 and AMPK may drive unbalanced metabolism in starved tumor cells, promoting apoptosis.
Researchers successfully developed bispecific antibodies that can target and deplete cancer cells without damaging healthy ones, including mutant tumor suppressor genes like p53. These antibodies could be used 'off-the-shelf' and are a promising alternative to engineered immune cell therapies.
Researchers at SCCL have found that CD4 T lymphocytes, which typically support immune responses, can also kill cancer cells directly. Up to a third of these cells were able to destroy tumor cells within five hours.
Researchers at Max Delbréck Center for Molecular Medicine in the Helmholtz Association have made significant findings on the role of chromatin modulators in tumor cell identity changes. By using a combination of CRISPR and molecular reporter technology, they found that chromatin proteins significantly influence how tumor cells change t...
Scientists visualized anti-CD20 antibody effects in tumors using innovative imaging, finding macrophages play a crucial role in therapy efficacy. The study suggests increasing macrophage presence could boost therapeutic antibody effectiveness.
Researchers use zebrafish to study human cancer and discover that the innate immune system actively destroys cancer cells. However, tumor cells can adapt and evade immune detection through a process called 'Immunoediting', leading to immunotherapy resistance.
Researchers discovered that human tumours contain solid and fluid cell clusters, enabling cancer cells to move and multiply. The study's findings could lead to improved cancer diagnosis and therapy, with potential applications in detecting metastatic cancer cells.
Researchers develop a new protein, 161519 TriKE, to target cold tumors and enhance the immune response. The study found that 161519 TriKE successfully reduced tumor growth and increased overall survival in tumor-bearing mice.
Researchers studied cell interactions in a microscopic 'cell collider' and found that normal cells repel each other's protrusions, while cancer cells try to squeeze past each other. The study suggests new approaches for understanding cancer cell behavior and identifying molecular bases for these differences.
This review article highlights the complex crosstalk between cancer stem cells (CSCs) and tumor-associated macrophages (TAMs), two key players in cancer progression. CSCs have been identified as the drivers of cancer initiation and progression, while TAMs create a protective microenvironment for CSC development and dissemination.
Scientists have identified CD161 as a potential new target for immunotherapy of malignant brain tumors, including glioblastoma. The molecule suppresses the cancer-fighting activity of immune T cells, but blocking its pathway enhances the killing of tumor cells and improves survival rates in animal models.
Researchers discovered that immunomodulatory drugs like lenalidomide and pomalidomide starve cancer cells by destabilizing essential surface proteins, ultimately inhibiting tumor growth. This finding opens up new possibilities for targeted therapies in multiple myeloma.
Researchers found that non-metastatic cells can spread to distant organs through a new mechanism involving the fibrotic niche induced by malignant cells. This discovery suggests targeting the fibrotic niche as a promising strategy to control solid tumor progression.
Researchers at Technion-Israel Institute of Technology have discovered a new pathway that targets cancer cells specifically, minimizing damage to healthy cells. The folate cycle is essential for DNA and RNA production, and the team found that tumor cells relying on the cytosolic pathway are more susceptible to targeted treatments.
Researchers at MIT have devised a way to label and sequence individual RNA molecules within a tissue sample, allowing for a unique snapshot of which genes are being expressed in different parts of a cell. This technique offers new insights into how gene expression is influenced by a cell's location or its interactions with nearby cells.
Researchers at Tokyo University of Science explore the structure of porphyrin derivatives to selectively target cancer cells and improve drug delivery. They found that meso-derivatives accumulate in cells at 3-fold higher amounts than β-derivatives, and that smaller functional groups allow better aggregation.
Researchers have identified a little-known glycoprotein called stanniocalcin-1 that blocks the immune system's ability to fight cancer cells. By targeting this pathway, scientists hope to improve response rates to cancer immunotherapy treatments.
Researchers at Boston University School of Medicine have identified genetic dependencies in tumors that have undergone whole genome doubling. The study found that WGD tumor cells possess unique vulnerabilities that can be targeted by new therapeutics.
Researchers developed a BCL strategy to generate highly potent tumor-targeted drugs from non-toxic compounds within the tumor, avoiding decomposition and side effects. The targeting drug Ru-rhein exhibits high anti-cancer activity against lung cancer cells while being non-toxic to normal cells.
Researchers at UT Southwestern Medical Center have discovered that removing a key gene called Cbl-b can revitalize exhausted CD8+ T cells to combat malignant tumors. This breakthrough could offer a new approach to harnessing the body's immune system to fight cancers.
Researchers at Moffitt Cancer Center discovered that cancer cells can fuse and recombine their genetic material, leading to increased diversity and adaptability. This mechanism, similar to parasexual recombination in pathogenic microbes, enables cancer cells to rapidly evolve and acquire resistance to treatments.
Cancer cells can thrive in hostile environments through metabolic adaptation known as the Warburg Effect. Moffitt researchers found that activation of transcription factor KLF4 allows cells to select for this phenotype, enabling them to survive and thrive in poor conditions.
Researchers from UC3M and UCM developed a mathematical model to understand how cancer cells invade healthy tissue, using topological data analysis techniques. The model simulates the collective movement of cells in tissues and can be used to track the progression of tumor growth.
Researchers developed CopyKAT, a new computational technique that accurately differentiates between cancer and normal cells in solid tumor samples. The tool uses gene expression data to identify aneuploidy and distinct subpopulations within cancer cells.
A new study published in Cell reveals that RNA splicing therapeutics can activate antiviral immune pathways in triple negative breast cancers, triggering tumor cell death and signaling the body's immune response. The discovery highlights a novel mechanism for turning on the immune system in aggressive cancers.
Researchers developed a gene expression signature that robustly predicts patient survival in patients with peritoneal carcinomatosis, a form of metastatic gastric cancer. The signature is associated with tumor cell populations and lineage compositions, offering potential for tailored treatment strategies.
Researchers have developed molecular reporters that reveal how immune cells strengthen brain tumors, making them more aggressive. The technology has the potential to guide therapy development and is applicable to various biological systems.
Researchers have developed nanoparticles that can breach cell barriers and kill tumor cells, reducing tumor sizes by 40-70% in mice. The highly selective toxicity of the particles offers new hope for treating aggressive cancers.
Researchers found that targeting the fas protein can prevent cancer cells from escaping immunotherapies, leading to longer-lasting positive responses and improved survival rates. By combining immunotherapies with small molecule inhibitors, bystander tumor cell killing may be potentiated to eliminate antigen-loss variants.
Researchers developed inhibitors targeting mitochondrial DNA, affecting only rapidly dividing cells like cancer cells. Treatment stopped cell proliferation and reduced tumour growth without harming healthy cells.
Research suggests stress hormones and immune cells may contribute to tumor recurrence by reactivating dormant cancer cells. Targeting stress hormones with approved drugs like beta-blockers could potentially prevent tumors from returning.
Researchers at Brigham and Women's Hospital developed a small-molecule inhibitor targeting SerpinB9 protein in cancer cells, weakening its defense mechanisms and triggering cell death. The approach shows promise for treating 'cold tumors' that evade immunotherapies.
A study by Harvard Medical School scientists reveals a transient, cooperative interaction between ovarian cancer cells that allows nonmetastatic tumor cells to invade distant sites. The team identified amplified ERBB2 levels in a specific cell population, which was activated by amphiregulin, a signaling protein found in advanced ovaria...
The new WEHI-TV animation explains how the 'tumour suppressor' protein p53 prevents cancer-causing changes in cells. More than half of human cancers involve faulty p53, and researchers are still working to develop better therapies for these cancers.
Researchers have identified a gene, VSIG1, that prevents the development of metastatic tumour cells, enabling targeted therapies to be developed. The study validates the use of spiked-scRNAseq technology for testing drugs against metastases, including personalized approaches.
Researchers from Tokyo Medical and Dental University identify TruB1 as a regulator of the microRNA let-7, which has significant implications for cancer development and suppression. The study reveals that TruB1 promotes maturation of let-7 and suppresses cell growth and division.
Pancreatic cancer cells use nerve growth factor to signal nerves to grow into dense tumors and secrete nutrients like serine. This allows the cancer cells to multiply despite nutrient starvation, highlighting a unique adaptation that contributes to their deadliness.
This study examines the effects of talc on mesothelial and neoplastic cells, revealing high levels of IL-6 and TNFRI. The results suggest that normal mesothelium is the main stimulus for the inflammatory process, with talc inducing higher rates of apoptosis in neoplastic cells.
Researchers at Swiss Federal Institute of Technology and Philochem AG describe four novel formats for L19-IL2 fusion proteins, featuring different arrangements of antibody and IL2, which exhibit superior tumor-targeting properties in vivo. The new format also reduces activation of regulatory T cells.
A new technique developed at Scripps Research isolates tumor-reactive immune cells in just one day, offering a platform for personalized cancer treatments. The method, called FucoID, detects and tags the surface of sought-after immune cells using an enzyme, enabling their detection with fluorescent probes.
A new study by Brown University scientists has identified vimentin as a potential target for treating aggressive cancer cells known as polyploidal giant cancer cells (PGCCs). PGCCs have been found to rely on vimentin to migrate and invade surrounding tissues.
Researchers have discovered that cancer cells use their nucleus to sense environmental compression and trigger responses to evade overcrowded areas. The study proposes a new mechanism by which tumor cells cope with the lack of space and compressive stresses, involving the unfolded and stretched nuclear membranes.
Researchers developed nanoparticles that release bursts of calcium inside tumor cells, inhibiting drug pumps and reversing MDR. The treatment showed significantly smaller tumors in tumor-bearing mice with no apparent side effects.
Researchers define two molecular subtypes of pancreatic carcinoma with distinct aggressiveness, differing in the origin and development. The study reveals a novel mechanism called viral mimicry that promotes cancer growth and metastasis.
Researchers discovered that immune system T cells can home-in on tumor cells independently of intermediary immune cells and release chemical signals that attract more T cells. This 'swarming' behavior could help develop new cancer therapies targeting solid tumors, currently less responsive to immunotherapies.
Scientists from Germany and China combine chemotherapeutic and photodynamic agents in a nanocapsule to destroy cancer cells. The treatment is effective against resistant tumors and stops tumor growth in live mice, offering a promising new approach to cancer therapy.
Researchers from RUDN University have developed a novel domino reaction for synthesizing chromenoisoquinolineamine derivatives, which showed promising antitumor activity against cancer cells, including drug-resistant strains. The new compounds were found to be toxic to tumor cells and efficient even at low concentrations.
Researchers at CNIO successfully applied CRISPR technology to eliminate fusion genes causing tumors, leading to the death of cancer cells while leaving healthy cells unaffected. This breakthrough approach could lead to the development of targeted cancer therapies.
This study reveals that hypoxic exosomes promote sphere formation and stem-like phenotype in EWS cells by delivering enriched miR-210. The knockdown of HIF-1α led to decreased exosomal miR-210 levels, while inhibition of miR-210 attenuated sphere formation.
A new potential drug treatment has been discovered for a type of lung-cancer. Researchers have found that combining osimertinib with linsitinib can cure or delay tumor recurrence in EGFR-mutated lung cancer, even in AXL-low expressing tumors.
Researchers discover that the proteins transforming growth factor-β (TGF-β) and tumor necrosis factor alpha (TNF-α) promote the development of cancer-associated fibroblasts, contributing to tumor progression. TGF-β induces endothelial-mesenchymal transition (EndMT), a process involving the conversion of endothelial cells to CAFs.